Back to discover
Disease

Atrial fibrillation, familial, 10

Late-stage therapeutic development

Also known as SCN5A familial atrial fibrillation, atrial fibrillation, familial, type 10, familial atrial fibrillation caused by mutation in SCN5A, ATFB10.

23
Clinical trials
1
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 2 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Major developments
Major clinical milestoneHigh impact
Rationale and Design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial
Primary completion2026-09-30
Upcoming trial readoutImportant
Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias
Results expected Q1 20272026-04-14
Clinical Milestones9View all 9
Results expected 2
Recently completed 5
Other updates 2
+1 more in the activity timeline below
Activity timeline9

Clinical trials

17 sponsors · 0 new · 4 completed in the last 12 months (net -2)

The current development programme across all trial phases.

Clinical programme
23
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF).

Phase 4 · Active, not recruiting · Herlev and Gentofte Hospital

Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias

Phase 4 · Active, not recruiting · Vivek Reddy

Rationale and Design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial

Phase 4 · Active, not recruiting · The University of Hong Kong

Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia: A Prospective Multicenter Study

Phase 4 · Active, not recruiting · Centre Hospitalier de PAU

An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation

Phase 3 · Completed · Novartis

EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

Phase 4 · Completed · Population Health Research Institute
Recently completed

EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

Phase 4 · Completed · Population Health Research Institute

Stellate Ganglion Blockade for the Prevention of Atrial Fibrillation After Cardiac Surgery: A Randomized Placebo-Controlled Trial

Phase 2/3 · Completed · Mayo Clinic

Escalated Single Platelet Inhibition for One Month Plus Direct Oral Anticoagulation in Patients With Atrial Fibrillation and acUte coRonary Syndrome Undergoing percutaneoUS Coronary Intervention

Phase 4 · Completed · Ludwig-Maximilians - University of Munich

Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents (ADAPT AF-DES)

Phase 4 · Completed · Yonsei University

An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation

Phase 3 · Completed · Novartis

A Comparison of the Effectiveness of Carvedilol Versus Metoprolol for Atrial Fibrillation Appearing After Off-Pump Coronary Bypass Surgery in the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT)

N/A · Completed · Ministry of Health, Labour and Welfare, Japan

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SCN5A0.80

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Sodium channel protein type 5 subunit alphavia SCN5A0.80

Reference

Authoritative identity, definition & identifiers.

Synonyms

SCN5A familial atrial fibrillation, atrial fibrillation, familial, type 10, familial atrial fibrillation caused by mutation in SCN5A, ATFB10

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.